• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肝细胞癌中抗肿瘤T细胞反应受损

Impaired Anti-Tumor T cell Response in Hepatocellular Carcinoma.

作者信息

Chaoul Nada, Mancarella Serena, Lupo Luigi, Giannelli Gianluigi, Dituri Francesco

机构信息

Department of Biomedical Sciences and Human Oncology, University of Bari Medical School, 70124 Bari, Italy.

National Institute of Gastroenterology "S. De Bellis," Research Hospital, 70013 Castellana Grotte, Italy.

出版信息

Cancers (Basel). 2020 Mar 8;12(3):627. doi: 10.3390/cancers12030627.

DOI:10.3390/cancers12030627
PMID:32182707
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7139707/
Abstract

Different subsets of lymphocytes have the capacity to promote or counteract the progression of solid cancers, including hepatocellular carcinoma (HCC). Therefore, to determine the infiltrative ability and functional status of major immune cell subtypes into tumor may lead to novel insights from the perspective of immunotherapy. After obtaining single cell suspensions from freshly collected specimens of HCC tumor, along with paired peritumor tissues and peripheral blood mononuclear cells (PBMCs) from 14 patients, we flow-cytometrically identified and quantified the relative frequencies of lymphocyte subsets within the tissues of origin. We found that the recruitment in the tumor of cytotoxic cells, namely the terminally differentiated CD4+ and CD8+ T cells (TEFF), is impaired, whereas the effector memory CD4+ T cells (TEM) are more attracted in this site. Concerning the other subsets, the frequency of NK CD56hi and NKT CD56hi cells infiltration in the tumor is increased, whereas that of NKT CD56low is reduced. Although CD4+ and CD8+ T cells settled in the tumor show a higher degree of activation than the circulating counterpart, they occur with a more exhausted phenotype. Overall, these data demonstrate the prevalently immunosuppressive nature of HCC microenvironment, and prompt us to search for strategies to enhance the activity of anti-tumor immune cell subsets.

摘要

不同亚群的淋巴细胞有促进或对抗实体癌进展的能力,包括肝细胞癌(HCC)。因此,确定主要免疫细胞亚型浸润肿瘤的能力和功能状态可能会从免疫治疗的角度带来新的见解。从14例患者新鲜采集的HCC肿瘤标本以及配对的瘤旁组织和外周血单核细胞(PBMC)中获得单细胞悬液后,我们通过流式细胞术鉴定并定量了起源组织中淋巴细胞亚群的相对频率。我们发现,肿瘤中细胞毒性细胞(即终末分化的CD4+和CD8+ T细胞(TEFF))的募集受损,而效应记忆CD4+ T细胞(TEM)更易被吸引到该部位。关于其他亚群,肿瘤中NK CD56hi和NKT CD56hi细胞浸润的频率增加,而NKT CD56low细胞的浸润频率降低。尽管定居在肿瘤中的CD4+和CD8+ T细胞比循环中的对应细胞表现出更高程度的活化,但它们呈现出更耗竭的表型。总体而言,这些数据证明了HCC微环境普遍具有免疫抑制性质,并促使我们寻找增强抗肿瘤免疫细胞亚群活性的策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/45a7/7139707/c1b206b2d905/cancers-12-00627-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/45a7/7139707/fab776b7c4f6/cancers-12-00627-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/45a7/7139707/02a6c88361c7/cancers-12-00627-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/45a7/7139707/2933dbf8a157/cancers-12-00627-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/45a7/7139707/c1b206b2d905/cancers-12-00627-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/45a7/7139707/fab776b7c4f6/cancers-12-00627-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/45a7/7139707/02a6c88361c7/cancers-12-00627-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/45a7/7139707/2933dbf8a157/cancers-12-00627-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/45a7/7139707/c1b206b2d905/cancers-12-00627-g004.jpg

相似文献

1
Impaired Anti-Tumor T cell Response in Hepatocellular Carcinoma.肝细胞癌中抗肿瘤T细胞反应受损
Cancers (Basel). 2020 Mar 8;12(3):627. doi: 10.3390/cancers12030627.
2
CD8 T cells mediate the antitumor activity of frankincense and myrrh in hepatocellular carcinoma.CD8 T 细胞介导乳香和没药在肝细胞癌中的抗肿瘤活性。
J Transl Med. 2018 May 21;16(1):132. doi: 10.1186/s12967-018-1508-5.
3
Expression of co-stimulator 4-1BB molecule in hepatocellular carcinoma and adjacent non-tumor liver tissue, and its possible role in tumor immunity.共刺激分子4-1BB在肝细胞癌及癌旁非肿瘤肝组织中的表达及其在肿瘤免疫中的可能作用。
World J Gastroenterol. 2004 Jan 15;10(2):195-9. doi: 10.3748/wjg.v10.i2.195.
4
PD1 CD8 T cells correlate with exhausted signature and poor clinical outcome in hepatocellular carcinoma.PD1 CD8 T 细胞与肝癌衰竭特征和不良临床结局相关。
J Immunother Cancer. 2019 Nov 29;7(1):331. doi: 10.1186/s40425-019-0814-7.
5
Suppression of hepatocellular carcinoma growth via oral immune regulation towards tumor-associated antigens is associated with increased NKT and CD8+ lymphocytes.通过对肿瘤相关抗原进行口服免疫调节来抑制肝细胞癌生长与自然杀伤T细胞(NKT)和CD8 +淋巴细胞增多有关。
Oncology. 2004;66(4):323-30. doi: 10.1159/000078334.
6
NKT and CD8 lymphocytes mediate suppression of hepatocellular carcinoma growth via tumor antigen-pulsed dendritic cells.自然杀伤T细胞和CD8淋巴细胞通过肿瘤抗原负载的树突状细胞介导对肝细胞癌生长的抑制。
Int J Cancer. 2003 Aug 20;106(2):236-43. doi: 10.1002/ijc.11201.
7
Associations between infiltrating lymphocyte subsets and hepatocellular carcinoma.浸润性淋巴细胞亚群与肝细胞癌之间的关联。
Asian Pac J Cancer Prev. 2012;13(11):5909-13. doi: 10.7314/apjcp.2012.13.11.5909.
8
Delineation of an immunosuppressive gradient in hepatocellular carcinoma using high-dimensional proteomic and transcriptomic analyses.利用高维蛋白质组学和转录组学分析描绘肝细胞癌中的免疫抑制梯度。
Proc Natl Acad Sci U S A. 2017 Jul 18;114(29):E5900-E5909. doi: 10.1073/pnas.1706559114. Epub 2017 Jul 3.
9
Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.基质 PD-L1 阳性调节性 T 细胞和 PD-1 阳性 CD8 阳性 T 细胞定义了不同亚组非小细胞肺癌对 PD-1/PD-L1 阻断免疫治疗的反应。
J Thorac Oncol. 2018 Apr;13(4):521-532. doi: 10.1016/j.jtho.2017.11.132. Epub 2017 Dec 18.
10
Suppression of hepatocellular carcinoma by transplantation of ex-vivo immune-modulated NKT lymphocytes.通过移植体外免疫调节的NKT淋巴细胞抑制肝细胞癌
Int J Cancer. 2005 Jun 20;115(3):443-9. doi: 10.1002/ijc.20889.

引用本文的文献

1
Personalized Immunity: Neoantigen-Based Vaccines Revolutionizing Hepatocellular Carcinoma Treatment.个性化免疫:基于新抗原的疫苗正在彻底改变肝细胞癌的治疗方式。
Cancers (Basel). 2025 Jan 23;17(3):376. doi: 10.3390/cancers17030376.
2
Mutual causal effects between immune cells and hepatocellular carcinoma: a Mendelian randomization study.免疫细胞与肝细胞癌之间的相互因果关系:一项孟德尔随机化研究。
Discov Oncol. 2025 Jan 16;16(1):54. doi: 10.1007/s12672-025-01785-z.
3
The Role of CD4T Cells in Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma.

本文引用的文献

1
Increased frequency and FOXP3 expression of human CD8CD25 T lymphocytes and its relation to CD4 regulatory T cells in patients with hepatocellular carcinoma.肝癌患者外周血 CD8CD25T 淋巴细胞频数及其 FOXP3 表达的变化及其与 CD4 调节性 T 细胞的关系。
Hum Immunol. 2019 Jul;80(7):510-516. doi: 10.1016/j.humimm.2019.03.014. Epub 2019 Mar 20.
2
Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression.肿瘤进展过程中髓源性抑制细胞(MDSCs)介导的免疫抑制。
Br J Cancer. 2019 Jan;120(1):16-25. doi: 10.1038/s41416-018-0333-1. Epub 2018 Nov 9.
3
Resistance a major hindrance to chemotherapy in hepatocellular carcinoma: an insight.
CD4T 细胞在非酒精性脂肪性肝炎和肝细胞癌中的作用。
Int J Mol Sci. 2024 Jun 23;25(13):6895. doi: 10.3390/ijms25136895.
4
Exploiting gender-based biomarkers and drug targets: advancing personalized therapeutic strategies in hepatocellular carcinoma.利用基于性别的生物标志物和药物靶点:推进肝细胞癌的个性化治疗策略
Front Pharmacol. 2024 Jun 20;15:1433540. doi: 10.3389/fphar.2024.1433540. eCollection 2024.
5
Hepatocellular Carcinoma and the Multifaceted Relationship with Its Microenvironment: Attacking the Hepatocellular Carcinoma Defensive Fortress.肝细胞癌及其与微环境的多方面关系:攻克肝细胞癌的防御堡垒
Cancers (Basel). 2024 May 11;16(10):1837. doi: 10.3390/cancers16101837.
6
Glycogen metabolism-mediated intercellular communication in the tumor microenvironment influences liver cancer prognosis.糖元代谢介导的肿瘤微环境中的细胞间通讯影响肝癌预后。
Oncol Res. 2024 Feb 6;32(3):563-576. doi: 10.32604/or.2023.029697. eCollection 2024.
7
BCG as an Innovative Option for HCC Treatment: Repurposing and Mechanistic Insights.BCG 作为 HCC 治疗的创新选择:再利用和机制见解。
Adv Sci (Weinh). 2024 Apr;11(14):e2308242. doi: 10.1002/advs.202308242. Epub 2024 Feb 2.
8
Peripheral immune characteristics of hepatitis B virus-related hepatocellular carcinoma.乙型肝炎病毒相关性肝细胞癌的外周免疫特征。
Front Immunol. 2023 Apr 3;14:1079495. doi: 10.3389/fimmu.2023.1079495. eCollection 2023.
9
Anti-neoplastic sulfonamides alter the metabolic homeostasis and disrupt the suppressor activity of regulatory T cells.抗肿瘤磺胺类药物改变代谢稳态并破坏调节性 T 细胞的抑制活性。
Sci Rep. 2022 Nov 9;12(1):19112. doi: 10.1038/s41598-022-23601-2.
10
PI3K/AKT/mTOR Pathway-Associated Genes Reveal a Putative Prognostic Signature Correlated with Immune Infiltration in Hepatocellular Carcinoma.PI3K/AKT/mTOR 通路相关基因揭示了与肝细胞癌免疫浸润相关的潜在预后特征。
Dis Markers. 2022 May 9;2022:7545666. doi: 10.1155/2022/7545666. eCollection 2022.
耐药性是肝细胞癌化疗的主要障碍:一项深入研究
Cancer Cell Int. 2018 Mar 20;18:44. doi: 10.1186/s12935-018-0538-7. eCollection 2018.
4
Hypoxia inducible factor HIF-1 promotes myeloid-derived suppressor cells accumulation through ENTPD2/CD39L1 in hepatocellular carcinoma.缺氧诱导因子HIF-1通过ENTPD2/CD39L1促进肝癌中髓源性抑制细胞的积累。
Nat Commun. 2017 Sep 11;8(1):517. doi: 10.1038/s41467-017-00530-7.
5
The future of immune checkpoint cancer therapy after PD-1 and CTLA-4.PD-1和CTLA-4之后免疫检查点癌症治疗的未来。
Immunotherapy. 2017 Jun;9(8):681-692. doi: 10.2217/imt-2017-0024.
6
Landscape of Infiltrating T Cells in Liver Cancer Revealed by Single-Cell Sequencing.单细胞测序揭示肝癌浸润 T 细胞景观。
Cell. 2017 Jun 15;169(7):1342-1356.e16. doi: 10.1016/j.cell.2017.05.035.
7
Systemic therapy for advanced hepatocellular carcinoma: an update.晚期肝细胞癌的系统治疗:最新进展
J Gastrointest Oncol. 2017 Apr;8(2):243-255. doi: 10.21037/jgo.2017.02.01.
8
Foxp3 Reprograms T Cell Metabolism to Function in Low-Glucose, High-Lactate Environments.Foxp3重编程T细胞代谢以在低糖、高乳酸环境中发挥功能。
Cell Metab. 2017 Jun 6;25(6):1282-1293.e7. doi: 10.1016/j.cmet.2016.12.018. Epub 2017 Apr 13.
9
Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies.癌症免疫疗法——免疫检查点阻断及相关内分泌病变
Nat Rev Endocrinol. 2017 Apr;13(4):195-207. doi: 10.1038/nrendo.2016.205. Epub 2017 Jan 20.
10
Atypical autoimmune adverse effects with checkpoint blockade therapies.检查点阻断疗法的非典型自身免疫不良反应。
Ann Oncol. 2017 Feb 1;28(2):206-207. doi: 10.1093/annonc/mdw658.